Tim Spong, Founder - VistaPath Bio


Manage episode 294491890 series 2519822
By Sal Daher. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Sponsored by Peter Fasse of Fish & Richardson: https://www.fr.com/team/j-peter-fasse/

To Join Sal's Syndicate: Click Here

A terrible error in a lab led Tim Spong to start a company to improve the reliability and efficiency of pathology labs; big industry players are noticing. This interview was part of my due diligence on Tim’s startup, VistaPath Bio. Subsequently, I invested in the company.

Highlights include:

  • Sal Daher Introduces Tim Spong, Co-Founder of VistaPath Bio
  • “Fast forward a hundred years, even if you walked into some of the best labs in the country, it's still a room full of people cutting tissue and staining tissue and sitting over jars.”
  • “…VistaPath is really aiming to do is build the next generation pathology lab using automation, AI, advanced imaging practices, and then put that into every lab in the world…”
  • “The rest of the time and a lot of the costs is spent in these labs, in histology labs, making the slides so that a pathologist can render a diagnosis.”
  • The Horror Story that Motivates Tim Spong to Improve the Lab Sample Workflow
  • How Tim Spong Connected with His Co-founder Ben Burley
  • “When I decided to actually quit my job and do it, it was really with him. We made that leap together. Like I said, he is amazing. I couldn't imagine getting this far without him.”
  • VistaPath Has Had to Overcome Investors’ Lack of Interest in Pathology
  • VistaPath Has a Smart Benchtop for Grossing of Samples that Is Equipped with Cameras to Reduce Error and Automate the Process
  • VistaPath Business Model
  • “What we wanted to do with our business model is make our product something that anybody could have, any lab could afford…”
  • “…our initial evaluations, we're already seeing that we're more accurate than humans, much faster than humans.”
  • “We really strove and worked a long time to make our products something that someone can take out of a box, plug into a lab, it's an easy-to-use interface, and they can use it as part of their workflow immediately.”
  • Sal Daher Is Considering Making an Investment in VistaPath Bio
  • Sal Daher Invites Accredited Investors to Join His Syndicate List
  • Tim’s Entrepreneurial Journey
  • Tim Spong Met His Wife at a Pathology Lab
  • Tim Spong Credits Advisors for Helping Him Decide to Become a Founder
  • “Some people have led us to some of our best advisors and investors were investors that actually turned us down.”
  • Tim Spong Encourages Industry Experts to Start Companies to Solve the Problems they See First-Hand

197 episodes